Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation

Clinical Chemistry

Volumn 57, Issue 7, 2011, Pages 983-985

  Bloom, Kenneth J ^a   Cote, Richard J ^b  

^a GE HEALTHCARE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

BREAST CANCER; CHROMOSOME 17; CHROMOSOME ANALYSIS; COLD ISCHEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; FIXATION DEVICE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY TEST; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR CELL; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NOTE; PATHOLOGY; STOMACH TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 79959734128     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.160853     Document Type: Short Survey

References (11)

1. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4. (Pubitemid 34705057)
2. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7. (Pubitemid 34705058)
3. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307-15.
4. Willmore-Payne C, Metzger K, Layfield LJ. Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 2007;15:84-7. (Pubitemid 46673322)
5. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:1457-67.
6. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2010;117:48-53.
7. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24.
8. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009;10:267-77.
9. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Oncol 2004;121:620-30. (Pubitemid 38533993)
10. Dowsett M, Hanby AM, Laing R, Walker R, for the National HER2 Consultation Steering Group. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 2007;60:685-9. (Pubitemid 46975226)
11. Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 2009;131:678-82.